SCHEMBL6401746

SCHEMBL6401746

CC(CCNC(=O)OCc1ccccc1)CC(=O)N(CCCc1ccccc1)CS(=O)(=O)Nc1cccc(C(C)O)c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.42
CHRNB2 P17787 1/20 0.38
CHRNB4 P30926 1/20 0.38
CHRNA3 P32297 1/20 0.38
CHRNA4 P43681 1/20 0.38
PPARG P37231 2/20 0.37
CASP1 P29466 1/20 0.37
MMP2 P08253 3/20 0.36
MMP9 P14780 3/20 0.36
MMP3 P08254 3/20 0.36
MMP14 P50281 2/20 0.36
MMP1 P03956 1/20 0.36
MMP7 P09237 1/20 0.36
CACNA1H O95180 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
HTT P42858 1/20 0.35
SLC1A3 P43003 1/20 0.35
SLC1A1 P43005 1/20 0.35
KCNA5 P22460 2/20 0.35
FOLH1 Q04609 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6403042 0.89 HTT (0.41) LMNACHRNB2CHRNB4CHRNA3CHRNA4
SCHEMBL6407167 0.85 CA1 (0.42) LMNACHRNB2CHRNB4CHRNA3CHRNA4
SCHEMBL6401980 0.79 LMNA (0.45) LMNAPPARGCACNA1H
SCHEMBL6401745 0.79 LMNA (0.45) LMNAPPARGCACNA1H
SCHEMBL6403803 0.79 KMT2A (0.45) LMNAHTT
SCHEMBL7253042 0.73 PTGES (0.42)
SCHEMBL6409458 0.73 NPC1 (0.42) LMNA
SCHEMBL6408733 0.72 CA1 (0.42) LMNAMMP2MMP3MMP1CA1
SCHEMBL6404595 0.72 LMNA (0.48) LMNAMMP3
SCHEMBL7253037 0.71 LMNA (0.46) LMNAPPARGMMP2MMP9MMP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6900237-B2 Sulfonamide compounds as protease inhibitors AXYS PHARMACEUTICALS, INC. (US) 2005-05-31 US disclosed
US-20030158231-A1 Sulfonamide compounds as protease inhibitors Celera Corporation 2003-08-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030158231-A1 Sulfonamide compounds as protease inhibitors PRSS1, PRSS3, SPINT2 LMNA 3804/4885CHRNB2 4860/4885CHRNB4 4869/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.